Antineoplastic Drugs API (75)
Showing 25–36 of 75 products · Page 3 of 7
Doxifluridine
Deoxyfluorouracil is a kind of fluorouracil derivatives, which is converted from the high activity pyrimidine nucleoside phosphorylase in tumor tissue to 5-Fu, and plays its selective anti-tumor role. The test shows that the therapeutic index of deoxyfluuridine is higher than that of 5-FU. As a precursor drug, deoxyfluuridine has better targeting, so it has better therapeutic effect and lower side effects in clinical, which has significant clinical significance for increasing the compliance of patients.
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride CAS 25316-40-9
Epirubicin
Epirubicin is one of the drugs selected to treat solid tumors. It acts directly on DNA, interferes with and prevents DNA replication and transcription. It affects the function of mitochondria by inhibiting the activities of respiratory enzymes such as succinate oxidase and NADPH oxidase. It has been found that it can induce apoptosis of cancer cells, which may occur through the mitochondrial pathway of apoptosis. Due to its excretion through the hepatobiliary system, the patients with liver dysfunction should be reduced to avoid accumulation of poisoning; for patients with moderate liver dysfunction (bilirubin 1.4-3mg / 100ml or BSP retention 9-15%), the dosage should be reduced by 50%; for patients with severe liver dysfunction (bilirubin > 3mg / 100ml or BSP retention > 15%), the dosage should be reduced by 75%; for patients with moderate renal dysfunction, there is no need to reduce the dosage, because Only a small amount of the drug is excreted through the kidney. The usage is intravenous administration. It is suggested to inject normal saline first to check the patency of the infusion tube and after the injection needle is indeed in the vein, then to give medicine through the patency of the infusion tube. This method can reduce the risk of drug spillover and ensure that the vein is flushed with saline after administration. If epirubicin overflows the vein during injection, it will cause serious tissue damage or even necrosis. If the same vein is injected in small vein or repeatedly, it will cause venous sclerosis. It cannot be mixed with heparin, because the chemical properties of the two are not compatible, and precipitation reaction will occur at a certain concentration. It can be used with other anti-tumor drugs, but the dosage of epirubicin should be reduced, not in the same syringe Mixed drugs.
Erlotinib Hydrochloride
Erlotinib hydrochloride is a small molecule reversible inhibitor of epidermal growth factor receptor tyrosine kinase, which is mainly used in the second-line or third-line treatment of locally advanced or metastatic non-small cell lung cancer and the treatment of pancreatic cancer.
Everolimus
Everolimus is a derivative of sirolimus, also known as 40-o - (2-hydroxyethyl) - rapamycin, or 40-o - (2-hydroxyethyl) - sirolimus. It is a kind of kinase drug that interferes with cell communication and prevents tumor cell growth. It is an oral mammalian rapamycin (mTOR) inhibitor. In the past, it was mainly used to prevent rejection after kidney transplantation and heart transplantation. At present, it can also be used in the treatment of advanced renal cancer patients who have used two inhibitors of vascular endothelial growth factor receptor kinase: SUTENT (Pfizer) and Nexavar (Bayer), with slight side effects.
Exemestane
Exemestane is an irreversible steroidal aromatase inhibitors, has similar structure with its substrate,natural androstenedione. And it is the pseudo substrate of aromatase . The inhibition of aromatase to estrogen deprivation is a effective method in the treatment of postmenopausal women with hormone dependent breast cancer.
Flumazenil
The first benzodiazepine antagonist is used to resist the sedation and disorientation of benzodiazepine drugs after over dose use, and has anticonvulsant activity and antiepileptic effect. It can also be used in the recovery period after halothane anesthesia and encephalopathy due to liver hardening caused by alcoholism, as a diagnostic drug for unknown loss of mind, to identify benzodiazepines and Other drugs poisoning or brain injury.
Gefitinib
Gefitinib is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
Gemcitabine
Gemcitabine is an anti-tumor drug, similar to pyrimidine, a new type of difluorocarbamide, which can be used in combination with cisplatin in the treatment of non-small cell lung cancer, or in the treatment of advanced or metastatic pancreatic cancer. Gemcitabine is also a bone marrow inhibitor, so the blood cell count should be checked during the treatment period (especially before each intravenous infusion).
Gimeracil
Tegafur is the actual chemotherapeutic agent. It is a prodrug of the active substance fluorouracil (5-FU).Gimeracil inhibits the degradation of fluorouracil by reversibly blocking a dehydrogenase enzyme. This results in higher 5-FU levels and a prolonged half-life of the substance.Oteracil mainly stays in the gut because of its low permeability, where it reduces the production of 5-FU by blocking the enzyme orotate phosphoribosyltransferase. Lower 5-FU levels in the gut result in a lower gastrointestinal toxicity.
Granisetron Hydrochloride
Granisetron hydrochloride has high receptor selectivity. Its affinity with 5-HT3 receptor is 4000-10000 times of that with other receptors such as 5-HT1, 5-HT2, dopamine D1, D1, histamine H1, benzodiazepine and opioid receptor, while the difference of ondansetron is only 1000 times. The antiemetic rate of granisetron hydrochloride was 93%, 96% and 100% in three dose groups: 2 × 0.005, 2 × 0.05 and 2 × 0.5mg/kg (IV), while that of ondansetron 2 × 2.5mg/kg was 89%. According to the toxicity study, granisetron hydrochloride can achieve a good antiemetic effect at a small dose, with little side effect. The cardiovascular system was abnormal at high dose. As the clinical recommended dose of granisetron hydrochloride is very small (3mg / D), it is only the lowest dose used in animal experiments (< 1mg / kg = L / 25), so the clinical application is very safe. The pharmacokinetic study showed that the half-life (T1 / 2) of granisetron hydrochloride in patients was 9h, that in healthy people was 4h, that in the elderly was 7.7h, and that in young people was 4.9h. Granisetron hydrochloride is mainly metabolized in the liver. It is excreted in the form of 7-hydroxygranisetron hydrochloride and other metabolites through feces and urine. The plasma clearance rate of liver function damaged or liver metastasis cancer decreased, and the clearance rate of renal insufficiency was 1 / 4 of that of normal. A high first pass metabolism was observed by oral administration, with an absolute bioavailability of 60%.
Ibandronate sodium monohydrate
Indications: This product is used for the treatment of postmenopausal osteoporosis; for the treatment of bone pain caused by osteolytic bone metastasis of malignant tumors; for the treatment of hypercalcemia caused by malignant tumors with or without bone metastasis.
